Open-labeled(Part 1), Single-group(Part 2), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Pharse II Clinical Trial to Evaluate Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs GC 3114 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GC Pharma
- 03 Jan 2019 Status changed from active, no longer recruiting to completed.
- 15 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.